SGMT - NASDAQ

SB

Sagimet Biosciences Inc.

SGMTยทNASDAQ

$6.86

+1.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$223.51M
EPS-1.5800
P/E Ratio-4.34
Earnings Date08/12/2026
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT ยท NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

HIDDEN
Intrinsic Value
Current Price: $6.86

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$213.8M
+ Cash & Equivalents$35.0M
Firm Value-$178.8M
- Debt$78.0K
Equity Value-$178.9M
/ Shares Outstanding31,001,109B
DCF Value-$6
OVERVALUED BY 184%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$42.2M
-$39.0M
-$36.0M
-$33.3M
-$30.8M
-$28.5M
-$26.3M
-$24.3M
-$22.5M
-$20.8M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$42.2M
-$39.0M
-$36.0M
-$33.3M
-$30.8M
-$28.5M
-$26.3M
-$24.3M
-$22.5M
-$20.8M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$39.1M
-$33.4M
-$28.6M
-$24.5M
-$21.0M
-$17.9M
-$15.3M
-$13.1M
-$11.2M
-$9.6M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your SGMT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.